摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-dihydro-4H-thieno[3,2-c]pyran | 865187-86-6

中文名称
——
中文别名
——
英文名称
6,7-dihydro-4H-thieno[3,2-c]pyran
英文别名
——
6,7-dihydro-4H-thieno[3,2-c]pyran化学式
CAS
865187-86-6
化学式
C7H8OS
mdl
——
分子量
140.206
InChiKey
JKVQRPWUDNCFBD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    239.5±30.0 °C(Predicted)
  • 密度:
    1.200±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    37.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    6,7-dihydro-4H-thieno[3,2-c]pyranN-溴代丁二酰亚胺(NBS)N,N-二异丙基乙胺三苯基膦 作用下, 以 甲苯乙腈 为溶剂, 反应 36.0h, 生成 diethyl (2-fluorophenyl)-(2-bromo-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)methylphosphonate
    参考文献:
    名称:
    噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法 及用途
    摘要:
    本发明属于医药化工领域,涉及一种噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途。具体地,本发明涉及式I所示的化合物、其可药用盐、其消旋体、其立体异构体、或其溶剂化物,其中各取代基的定义如说明书中所述。本发明还涉及该化合物的药物组合物。本发明的化合物能够有效地抗血小板聚集和/或保护血管内皮细胞。
    公开号:
    CN102731574B
  • 作为产物:
    描述:
    2-(2-methoxymethoxyethyl)thiophene 在 magnesium bromide 作用下, 以 二氯甲烷 为溶剂, 反应 12.0h, 以82%的产率得到6,7-dihydro-4H-thieno[3,2-c]pyran
    参考文献:
    名称:
    [EN] METHOD OF PREPARING THIENO[3,2-C]PYRIDINE DERIVATIVES AND INTERMEDIATES USED THEREIN
    [FR] METHODE DE FABRICATION DE DERIVES DE THIENO[3,2-C]PYRIDINE ET INTERMEDIAIRES UTILISES DANS CES COMPOSES
    摘要:
    Ticlopidine和clopidogrel具有高血小板聚集抑制和抗血栓活性,可以通过将取代噻吩衍生物与2-氯苄胺衍生物反应简单制备。
    公开号:
    WO2005087779A1
点击查看最新优质反应信息

文献信息

  • NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES
    申请人:Hebeisen Paul
    公开号:US20090143448A1
    公开(公告)日:2009-06-04
    Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    式(I)的化合物以及其药用可接受的盐和酯,其中R1至R3具有权利要求1中给定的含义,并可用于制成药物组合物。
  • Merging Photoredox with Brønsted Acid Catalysis: The Cross-Dehydrogenative C−O Coupling for sp<sup>3</sup> C−H Bond Peroxidation
    作者:Qing Xia、Qiang Wang、Changcun Yan、Jianyang Dong、Hongjian Song、Ling Li、Yuxiu Liu、Qingmin Wang、Xiangming Liu、Haibin Song
    DOI:10.1002/chem.201701755
    日期:2017.8.10
    A photoredox and Brønsted acid synergistically catalyzed cross‐dehydrogenative C−O coupling reaction is developed in which isochroman peroxyacetals are formed through sp3 C−H bond peroxidation. The reported method is characterized by its extremely mild reaction conditions, excellent yields, and broad substrate scope. An oxocarbenium ion p‐chlorobenzenesulfonate was speculated to be the reactive intermediate
    开发了一种光氧化还原和布朗斯台德酸协同催化的交叉脱氢CO偶联反应,其中异铬烷过氧缩醛通过sp 3 C-H键过氧化反应形成。报道的方法的特点是反应条件极其温和,收率优异且底物范围广。氧碳鎓离子对氯苯磺酸被认为是反应性中间体。研究了半缩醛和含氧二聚体对氧碳鎓离子有效稳定的作用。酸的存在似乎建立了含氧碳鎓离子对的半缩醛和含氧二聚体之间的平衡。该方法的广泛适用性突出了该协议用于分子合成的潜力。
  • Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
    申请人:Merck Sharp & Dohme Corp.
    公开号:US20150307465A1
    公开(公告)日:2015-10-29
    In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.
    本发明提供了多种形式的亚氨基噻二唑二氧化物化合物,包括公式(I)的化合物: 包括它们的立体异构体,以及所述立体异构体的药用可接受盐,其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性,使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白(“Aβ”)生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物(单独使用和与一个或多个其他活性成分组合使用)的药物组合物,以及它们的制备方法和用于治疗与淀粉样β(Aβ)蛋白相关的病理学,包括阿尔茨海默病的方法。
  • [EN] INHIBITING TRABID<br/>[FR] INHIBITION DE TRABID
    申请人:INTEGRAL EARLY DISCOVERY INC
    公开号:WO2020227168A1
    公开(公告)日:2020-11-12
    The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with the inhibition of TRABID. For instance, the disclosure is concerned with compounds and compositions for inhibition of TRABID, methods of treating diseases associated with the inhibition of TRABID (e.g., autoimmune inflammatory diseases including, but not limited to, psoriasis), and methods of synthesis of these compounds.
    本公开涉及化合物的结构式(I) - (VII),这些化合物可作为TRABID的调节剂。这些化合物进一步可用于抑制TRABID并治疗与TRABID抑制相关的疾病或紊乱。例如,本公开涉及用于抑制TRABID的化合物和组合物,治疗与TRABID抑制相关的疾病的方法(例如,包括但不限于自身免疫性炎症性疾病,如牛皮癣),以及这些化合物的合成方法。
  • A g-C<sub>3</sub>N<sub>4</sub>-based heterogeneous photocatalyst for visible light mediated aerobic benzylic C–H oxygenations
    作者:Pengxin Geng、Yurong Tang、Guanglong Pan、Wentao Wang、Jinchuan Hu、Yunfei Cai
    DOI:10.1039/c9gc02870f
    日期:——
    A metal-free heterogeneous photocatalytic system has been developed for highly efficient benzylic C–H oxygenations using oxygen as an oxidant. This visible light mediated oxidation reaction utilizes graphitic carbon nitride (g-C3N4) as a recyclable, nontoxic and low cost photocatalyst. Mild reaction conditions allow for the generation of synthetically and biologically valued isochromannones, phthalides
    已开发出一种无金属的非均相光催化系统,用于使用氧气作为氧化剂的高效苄基CH氧化。这种可见光介导的氧化反应利用石墨碳氮化物(gC 3 N 4)作为可回收,无毒且低成本的光催化剂。温和的反应条件可从易于获得的烷基芳族前体中以高收率生成合成和生物学上有价值的异苯并二氢醌,邻苯二甲酸,异喹啉酮,异吲哚啉酮和氧杂蒽。gC 3 N 4的异质性催化系统可轻松回收和循环利用,并可多次使用而不会损失活性。通过在生物活性和具有药物价值的靶标合成中的应用,进一步证明了这种“绿色”方法的综合效用。
查看更多

同类化合物

化合物SEP-363856HYDROCHLORIDE 6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-甲胺 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸乙酯 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸 5,7-二氢-4H-噻吩并[2,3-c]吡喃-3-羧酸 5,7-二氢-4H-噻吩并[2,3-C]吡喃-3-羧酸乙酯 4-(2-羟基乙基)-4-甲基-6,7-二氢-4h-噻吩并[3,2-c]吡喃 4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 4',5'-二氢-螺[哌啶-4,7'-[7H]噻吩并[2,3-c]吡喃]-1-羧酸叔丁酯 2-氯-4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 2-氨基-5,5-二甲基-4,7-二氢-5H-噻吩并[2,3-C]吡喃-3-羧酸叔丁酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸乙酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-甲腈 2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸 (4-甲基-6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-基)乙酸 (2-羧基噻吩-3-基)乙酸酐 2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide 2-[[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-fluoronicotinamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-oxopyrrolidine-3-carboxamide 2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide tert-butyl 2-(3-(3,4-dimethoxyphenyl)thioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate trans-6-(benzyloxy)-2-carbamoyl-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-carbomethoxy-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-cyano-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-bromo-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran 5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-cyano-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran cis-7-amino-5,6-dihydro-6-hydroxy-5,5-dimethyl-5H-thieno<3,2-b>pyran 2-[3-(3-trifluoromethyl[1,2,4]oxadiazol-5-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4-trifluoromethylthiazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4,5-dimethyloxazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 4,4-dimethyl-6,7-dihydro-4H-thieno[3,2-c]pyran 1,1-(3-dimethylamino-3-phenyl-methylene)-3,4-dihydro-1H-2-oxa-9-thia-fluoren N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine triflate N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine trans-5,6-dihydro-6-hydroxy-2,5,5-trimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran 5-Cyclohexyl-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxylic acid tert-butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-5H-thieno[3,2-b]pyran-2-carbonitrile 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-2-(thiazolin-2-yl)-5-thieno[3,2-b]pyran